Durham (NC, USA) and Liege (Belgium) - May 12, 2010, 18:00 CET - OncoMethylome Sciences SA (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) reports that it received a transparency statement which shows that on May 6, 2010, Drs. Herman Spolders reduced his shareholding in the company from 3.28% to 2.96% of the total 13,185,614 outstanding shares of the company.
For further details on the transparency notifications received by the company, reference is made to our website www.oncomethylome.com.
About OncoMethylome Sciences
OncoMethylome Sciences is a leading molecular diagnostics company that commercializes and develops cancer-screening tests to assist physicians in detecting and treating cancer early. The company's tests are based on proprietary gene methylation technology invented at Johns Hopkins University and are designed to help the physician accurately detect early stages of cancer development, predict a patient's response to drug therapy, and predict the likelihood of cancer recurrence. OncoMethylome Sciences collaborates with leading cancer research centers, such as Johns Hopkins, in Baltimore, MD, and has a number of commercial and collaborative partnerships with LabCorp, Schering-Plough, GlaxoSmithKline Biologicals, Millipore Corporation's BioScience Division, Roche, Merck KGaA and Qiagen.
For more information:
Dr. Jan Groen
CEO
+32 4.364.20.70 office
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of OncoMethylome and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the Company's control, and may turn out to be materially different.
